Ruxolitinib versus standard treatments for high-risk polycythemia vera
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign written consent
- Your polycythemia vera (PV) diagnosis was made within the last 15 years
- You have “high-risk” PV (for example, high white blood cell count or age over 60, prior clot/bleeding, very high platelets, or needing medicine for high blood pressure or diabetes)
- Your hemoglobin is above 8 g/dl at screening
- You may have had one prior PV treatment (cytoreductive therapy) for less than 10 years, as long as it did not stop working for you
- You must have a JAK-2 mutation and you must not have had ruxolitinib before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This trial tests an investigational drug called rusfertide for people with polycythemia vera whose red blood cell levels are not well controlled. It aims to see if rusfertide can help manage your condition without needing as many phlebotomies (blood removal procedures).
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.